NCT05540223: A trial that was reported late by Biotronik, Inc.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT05540223 |
|---|---|
| Title | BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable Coronary MAGnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A Randomized Controlled Trial |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 30, 2023 |
| Completion date | March 31, 2026 |
| Required reporting date | March 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 26, 2023 |
| Days late | None |